Filing Flows › Edap TMS SA (FOCL) › Guidance & outlook
Edap TMS SA (FOCL) guidance and outlook
Edap TMS SA (FOCL) lowered its guidance on Nov 5, 2026: Revenue $50.0M–$52.0M for FY2026; Revenue +34% to +39% for FY2026. Edap TMS SA's 10-Q filed Nov 5, 2026 makes 7 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $50.0M–$52.0M | lowered |
| Revenue | FY2026 | +34% to +39% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- On May 28, 2026, our Board of Directors approved a plan to exit our ESWL and Distribution segments, and on May 29, 2026 we announced our rebrand to FocalTherics and our strategic realignment to focus exclusively on our robotic focal therapy business built around the Focal One ® HIFU platform.
- We expect to complete the disposals through one or more transactions within one year of the held-for-sale classification, and until completion the timing, structure and terms of any transaction remain subject to negotiation and execution risk.
- ● continued commercialization efforts and expansion of our sales and marketing infrastructure and programs to drive anticipated sales growth in the United States and elsewhere; and
- We have a history of operating losses and expect such losses to continue in the foreseeable future.
- Although the additional capital provides us with increased liquidity and is expected to support our operations beyond the next twelve months, we continue to expect operating losses for the foreseeable future.
- If we are unable to achieve profitability and positive cash flow from operations within the period supported by our existing liquidity, or if our capital requirements are greater than currently anticipated, we may require additional financing in the future.
- The determination of fair value less costs to sell requires management to use estimates and assumptions, including expected transaction perimeter, expected buyer interest, market-based pricing indications, projected cash flows, discount rates, and expected costs to sell.
Edap TMS SA's latest quarter
Edap TMS SA, Q3 2026: revenue $9.8M (+26% year over year), operating margin -79.1%, net loss $4.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Edap TMS SA raise or lower its guidance?
Edap TMS SA (FOCL) lowered its guidance on Nov 5, 2026: Revenue $50.0M–$52.0M for FY2026; Revenue +34% to +39% for FY2026.
What does Edap TMS SA expect?
On May 28, 2026, our Board of Directors approved a plan to exit our ESWL and Distribution segments, and on May 29, 2026 we announced our rebrand to FocalTherics and our strategic realignment to focus exclusively on our robotic focal therapy business built around the Focal One ® HIFU platform. We expect to complete the disposals through one or more transactions within one year of the held-for-sale classification, and until completion the timing, structure and terms of any transaction remain subject to negotiation and execution risk. ● continued commercialization efforts and expansion of our sal
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.